IDEC Y2B8 RADIOIMMUNOTHERAPY COMPARED TO RITUXAN IN RELAPSED B CELL LYMPHOMA

这是一项随机、III期、多中心、对照研究，比较了晚期、复发或难治性非霍奇金b细胞淋巴瘤患者单疗程的IDEC-Y2B8和一个疗程的Rituxan的疗效和安全性。一个疗程的IDEC-Y2B8包括影像学剂量的IDEC-In2B8，一周后单剂量的IDEC-Y2B8；IDEC-Y2B8和IDEC-In2B8之前均输注250 mg/m2 Rituxan。利妥昔单抗一个疗程包括4次375 mg/m2输注（每周一次× 4）。低级别或滤泡性NHL复发或常规化疗失败且现在需要治疗的患者将符合本研究的条件。符合研究纳入和排除标准的患者可以被纳入研究。

This is a randomized, Phase III, multi-center, controlled study comparing the efficacy and safety of a single course of IDEC-Y2B8 with a course of Rituxan in patients with advanced, relapsed or refractory non-Hodgkin's B-cell lymphoma. A course of IDEC-Y2B8 includes an imaging dose of IDEC-In2B8 followed one week later by a single dose of IDEC-Y2B8; both IDEC-Y2B8 and IDEC-In2B8 are preceded by an infusion of 250 mg/m2 Rituxan. A course of Rituxan includes four infusions of 375 mg/m2 (once weekly x 4) of Rituxan. Patients with low-grade or follicular NHL who have relapsed disease or have failed primary conventional chemotherapy and now require treatment will be eligible for this study. Patients meeting the study inclusion and exclusion criteria may be enrolled into the study.